AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +65

Coca-Cola, UnitedHealth, Sabra Health Care: CNBC’s Final Trades - AbbVie (NYSE:ABBV), Coca-Cola (NYSE:KO) - Benzinga

📈 Bill Baruch, founder and CIO of Blue Line Capital and Blue Creek Capital Management, selected AbbVie Inc. (NYSE: ABBV) as his final trade on CNBC.

🏥 On May 29, AbbVie received European Commission authorization to expand the label for VENCLYXTO® (venetoclax) to include new combinations for previously untreated chronic lymphocytic leukemia.

📈 AbbVie shares rose 1% to close at $227.23 during the trading session following the news and analyst coverage.

💰 The regulatory approval expands the drug's utility in treating a specific form of blood cancer, potentially opening new revenue streams for the oncology portfolio.

📊 CNBC's 'Final Trades' segment also highlighted positive momentum for Coca-Cola, UnitedHealth Group, and Sabra Health Care, though AbbVie was the primary focus of this specific ticker analysis.

Bullish Signals
  • AbbVie received a strong buy recommendation from Bill Baruch, a prominent figure in the investment community managing Blue Line Capital and Blue Creek Capital Management.
  • The European Commission has officially authorized an expanded label for VENCLYXTO® (venetoclax), allowing it to be used with additional combinations for previously untreated chronic lymphocytic leukemia.
  • AbbVie shares demonstrated positive momentum, rising 1% to settle at $227.23 during the session.
  • The regulatory expansion of venetoclax represents a significant milestone in the company's oncology pipeline, validating its R&D efforts in blood cancer treatments.
Full Analysis
CNBC's 'Final Trades' segment highlighted four specific investment picks from various market professionals, with AbbVie (NYSE: ABBV) selected by Bill Baruch, founder and CIO of Blue Line Capital and Blue Creek Capital Management. The article notes that AbbVie shares rose 1% to settle at $227.23 during the trading session. Supporting the bullish sentiment on AbbVie, the company recently announced on May 29 that the European Commission authorized an expanded label for its drug VENCLYXTO® (venetoclax). This regulatory approval includes additional combinations for treating previously untreated chronic lymphocytic leukemia, marking a significant expansion in the drug's approved indications. The broader CNBC 'Final Trades' segment also featured picks for UnitedHealth Group, Sabra Health Care, and Coca-Cola. Analysts Kevin Fischbeck of B of A Securities upgraded UnitedHealth to Buy with a higher price target, while Coca-Cola saw its operating margins expand to 35% and organic revenue climb by 10% in the first quarter. Despite the inclusion of other tickers like Sabra Health Care and UnitedHealth Group in the same article, the substantive news regarding AbbVie centers on the specific regulatory win for venetoclax and the endorsement from Bill Baruch. The stock's positive price movement aligns with these developments.